Drugs that contain Carbidopa; Levodopa
1. Drug name - DHIVY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(16 years from now) | |
Treatment: Treatment of parkinson's disease; method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 25MG;100MG | TABLET;ORAL | Prescription |
2. Drug name - RYTARY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
| US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(6 years from now) | |
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; method of providing a therapeutically effective and stable median blood plasma level of levodopa; Treatment of parkinson's disease; treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of post-encephalitic parkinsonism; treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of parkinson's disease; treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 23.75MG;95MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 36.25MG;145MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 48.75MG;195MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 61.25MG;245MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.